Alprazolam XR Extended-Release Tablets Recalled Due to Dissolution Failure
Viatris Inc. is recalling alprazolam XR 3mg tablets (lot EH8348) distributed nationwide due to failed dissolution testing. Tablets may not dissolve properly, potentially reducing drug effectiveness.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no illnesses or injuries reported. The hazard—failed tablet dissolution—represents a theoretical risk of harm (reduced drug effectiveness) rather than documented injury. Per the rubric, recalls with no reported harm and theoretical hazards score at most High (3).
Plain-English summary
Viatris Inc. is recalling alprazolam XR 3mg extended-release tablets (60-count bottles) due to failed dissolution testing. The affected lot is EH8348 with an expiration date of August 2023 and was distributed nationwide.
Testing revealed low out-of-specification dissolution test results, meaning tablets from this lot may not dissolve properly in the body. This could reduce the drug's effectiveness in treating anxiety and panic disorders.
Patients taking tablets from lot EH8348 should discontinue use and contact their healthcare provider for a replacement prescription. Pharmacies and healthcare facilities should not dispense this product.
The recalled product
- Product
- ALPRAZOLAM (ALPRAZOLAM)
- Brand
- ALPRAZOLAM
- Manufacturer
- Viatris Inc
- Affected units
- 6,789
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # EH8348
- exp. date August 2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ALPRAZOLAM
- HighNeolpharma Recalls Subpotent Alprazolam Tablets Nationwide
FDA (Drugs) · 2014-12-31
- SevereSandoz Recalls Alprazolam Tablets Due to Stainless Steel Particulates
FDA (Drugs) · 2014-08-06
- ModerateActavis Recalls Alprazolam 1 mg Tablets Due to Significant Tablet Erosion
FDA (Drugs) · 2014-03-19
- SevereActavis Recalls Alprazolam Tablets Due to Weight Specification Failures
FDA (Drugs) · 2013-12-04
Same manufacturer · Viatris Inc
See all →- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15
- ModeratePrescription Drug Cardura XL Recalled for Out-of-Specification Impurity
FDA (Drugs) · 2025-01-22
- HighPrescription Drug Cardura Recalled for Specification Failures in Manufacturing
FDA (Drugs) · 2025-01-22
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateAjanta Pharma Recalls Ranolazine Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
Similar recalls
- HighXanax XR Extended-Release Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-05-18
- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15
- ModerateActavis Recalls Alprazolam Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-03-12
- ModerateMylan Recalls Alprazolam Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2017-05-31
- HighMatzim LA Extended-Release Tablets Recalled for Dissolution Specification Failure
FDA (Drugs) · 2022-08-10
- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07